08 jun: Damark/vismand: Regeringen skal finde nye penge
10 jun: Overskud i APM´s containerforretning
09-06-2012 00:07:00

UPDATE: J&J to Record $600 Million Charge Due to Outstanding Lawsuits

Relateret indhold
Relateret debat
13 maj - 
We offer fresh cut bank instrument for lease/sale, such..

--J&J to take litigation charge of about $600 million in second quarter

--Charge deals with litigation surrounding drugs Risperdal, Invega and Natrecor

--Took $1.1 billion litigation charge in the fourth quarter of 2011

(Updated to include details of previous litigation charge in the third paragraph.)

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

In the fourth quarter, J&J recorded a $1.1 billion charge related to litigation settlements. At the time, Chief Financial Officer Dominic Caruso said the litigation costs were primarily linked to Risperdal. The company didn't have a similar charge in its April first-quarter report.

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

J&J also has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

--Anjali Athavaley contributed to this report.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 18:07 ET (22:07 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Mærsk: Gør nødløsninger for at beskytte græsk enhed - medie

30-06-2015 15:19:01
Maersk Line forsøger at holde sine græske aktiviteter upåvirket af den kapitalkontrol, der er indført i landet.Blandt andet har rederiet, for at komme uden om k..

Vestas/Jyske: Ordreestimater begynder at se forsigtige ud

30-06-2015 14:25:36
Andet kvartal lakker mod enden og hos Vestas kan man se tilbage på endnu et kvartal med god aktivitet i ordrebogen. I løbet af de tre måneder frem til udgangen ..

Aktier/middag: TDC synker til bunds i lyserødt C20

30-06-2015 11:31:12
Der er igen pil ned på det danske aktiemarked tirsdag, hvor investorerne fortsat skal forsøge at sluge, at der ikke kom en aftale på plads med Grækenland og lan..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Jyske: Ordreestimater begynder at se forsigtige ud
2
Græsk finansminister: Vi betaler ikke gælden til IMF - NY
3
Græsk/Nordea: Køb aktier trods Grækenlands-krise
4
Aktier/tendens: Ligger og vipper med chance for lille stigning
5
Vestas-konkurrent får ordre på gigantmølle i Chile

Relaterede aktiekurser

Johnson & Johnson 97,46 -0,2% Fald i aktiekurs
Omnicare Inc 94,25 0,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
1. juli 2015 03:54:40
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150624.2 - EUROWEB7 - 2015-07-01 03:54:40 - 2015-07-01 03:54:40 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x